{"title": "La vacuna de Novavax, Nuvaxovid\u2122 COVID-19, autorizada en la Uni\u00f3n Europea para adolescentes de 12 a 17 a\u00f1os", "author": "Novavax; Inc", "url": "https://www.prnewswire.com/news-releases/la-vacuna-de-novavax-nuvaxovid-tm-covid-19-autorizada-en-la-union-europea-para-adolescentes-de-12-a-17-anos-837575764.html", "hostname": "prnewswire.com", "description": "/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnolog\u00eda dedicada al desarrollo y la comercializaci\u00f3n de vacunas de nueva generaci\u00f3n contra...", "sitename": "PR Newswire", "date": "2022-07-05", "id": null, "license": null, "body": null, "comments": "Share this article", "commentsbody": null, "raw_text": null, "text": "La vacuna de Novavax, Nuvaxovid\u2122 COVID-19, autorizada en la Uni\u00f3n Europea para adolescentes de 12 a 17 a\u00f1os\n[Novavax, Inc.](/news/novavax%2C-inc./)\n05 Jul, 2022, 15:58 ET\n[]\n- La vacuna Nuvaxovid\u2122 COVID-19 es la primera opci\u00f3n basada en proteinas para adolescentes de 12 a 17 a\u00f1os en Europa\nGAITHERSBURG, Md., 5 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)), una empresa de biotecnolog\u00eda dedicada al desarrollo y la comercializaci\u00f3n de vacunas de nueva generaci\u00f3n contra enfermedades infecciosas graves, ha anunciado hoy que la Comisi\u00f3n Europea (CE) ha aprobado la autorizaci\u00f3n condicional de comercializaci\u00f3n ampliada (CMA) de la vacuna Nuvaxovid\u2122 (NVX-CoV2373) COVID-19 en la Uni\u00f3n Europea (UE) para adolescentes de 12 a 17 a\u00f1os. La aprobaci\u00f3n se produce tras la recomendaci\u00f3n positiva del Comit\u00e9 de Medicamentos de Uso Humano de la Agencia Europea del Medicamento el [23 de junio de 2022](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2297960184&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D4051581382%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-06-23-Novavax-COVID-19-Vaccine-Nuvaxovid-TM-Recommended-for-Expanded-Conditional-Marketing-Authorization-in-the-European-Union-by-CHMP-for-Adolescents-Aged-12-Through-17%26a%3DJune%2B23%252C%2B2022&a=23+de+junio+de+2022).\n\"Con esta autorizaci\u00f3n, estamos muy satisfechos de poder ofrecer nuestra vacuna Nuvaxovid COVID-19 a los adolescentes de la UE\", ha declarado Stanley C. Erck, Presidente y Consejero delegado de Novavax. \"Nuestra vacuna basada en prote\u00ednas se desarroll\u00f3 utilizando un enfoque innovador de la tecnolog\u00eda tradicional y ha demostrado su eficacia y seguridad tanto en adolescentes como en adultos\".\nLa autorizaci\u00f3n se bas\u00f3 en los datos de la\n[ampliaci\u00f3n pedi\u00e1trica](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2892827951&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3028641640%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial%26a%3Dpediatric%2Bexpansion&a=ampliaci%C3%B3n+pedi%C3%A1trica) en curso de PREVENT-19, un ensayo pivotal de fase 3 con 2.247 adolescentes de 12 a 17 a\u00f1os en 73 centros de Estados Unidos, para evaluar la seguridad, la efectividad (inmunogenicidad) y la eficacia de Nuvaxovid. En el ensayo, Nuvaxovid alcanz\u00f3 su objetivo principal de eficacia y demostr\u00f3 una eficacia cl\u00ednica global del 80% en un momento en el que la variante Delta era la cepa de SARS-CoV-2 predominante en los Estados Unidos.\nLos datos preliminares de seguridad del ensayo mostraron que la vacuna fue generalmente bien tolerada. Los acontecimientos adversos graves y severos fueron bajos en n\u00famero y equilibrados entre los grupos de vacuna y placebo, y no se consideraron relacionados con la vacuna. La reactogenicidad local y sist\u00e9mica fue en general inferior o similar a la de los adultos, despu\u00e9s de la primera y segunda dosis. Las reacciones adversas m\u00e1s comunes observadas fueron sensibilidad/dolor en el lugar de la inyecci\u00f3n, dolor de cabeza, mialgia, fatiga y malestar. No hubo un aumento de la reactogenicidad en los adolescentes m\u00e1s j\u00f3venes (12 a <15 a\u00f1os) en comparaci\u00f3n con los adolescentes mayores (15 a <18 a\u00f1os). No se observ\u00f3 ninguna nueva se\u00f1al de seguridad en la parte del estudio controlada con placebo.\nLa CE concedi\u00f3 la CMA para Nuvaxovid para prevenir la COVID-19 en individuos de 18 a\u00f1os o m\u00e1s en\n[diciembre de 2021](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2632041598&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D697197056%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D3782079808%2526u%253Dhttps%25253A%25252F%25252Fir.novavax.com%25252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%2526a%253DDecember%26a%3DDecember%2B2021&a=diciembre+de+2021). Adem\u00e1s de la CMA ampliada de la CE, la [India](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=574237381&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3307428078%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-03-22-Novavax-and-Serum-Institute-of-India-Announce-First-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-in-Adolescents-12-to-18-in-India%26a%3DIndia&a=India) ha concedido la autorizaci\u00f3n de uso de emergencia en la poblaci\u00f3n de 12 a 17 a\u00f1os.\nAutorizaci\u00f3n en Estados Unidos\nNVX-CoV2373 a\u00fan no ha sido autorizada para su uso en Estados Unidos y el nombre comercial Nuvaxovid\u2122 a\u00fan no ha sido aprobado por la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos.\nInformaci\u00f3n de seguridad importante\n- Nuvaxovid est\u00e1 contraindicado en personas con hipersensibilidad al principio activo o a cualquiera de los excipientes.\n- Se han notificado casos de anafilaxia con la administraci\u00f3n de las vacunas COVID-19. En caso de reacci\u00f3n anafil\u00e1ctica tras la administraci\u00f3n de la vacuna, debe disponerse de un tratamiento m\u00e9dico adecuado y de supervisi\u00f3n. Se recomienda una estrecha observaci\u00f3n durante al menos 15 minutos y no se debe administrar una segunda dosis de la vacuna a quienes hayan experimentado anafilaxia a la primera dosis de Nuvaxovid.\n- Pueden producirse reacciones relacionadas con la ansiedad, incluyendo reacciones vasovagales (s\u00edncopes), hiperventilaci\u00f3n o reacciones relacionadas con el estr\u00e9s en asociaci\u00f3n con la vacunaci\u00f3n como respuesta psic\u00f3gena a la inyecci\u00f3n de la aguja. Es importante tomar precauciones para evitar lesiones por desmayo.\n- La vacunaci\u00f3n debe posponerse en individuos que sufran una enfermedad febril grave o una infecci\u00f3n aguda. La presencia de una infecci\u00f3n menor y/o fiebre baja no debe retrasar la vacunaci\u00f3n.\n- Nuvaxovid debe administrarse con precauci\u00f3n en personas que reciban tratamiento anticoagulante o que padezcan trombocitopenia o cualquier trastorno de la coagulaci\u00f3n (como la hemofilia), ya que pueden producirse hemorragias o hematomas tras una administraci\u00f3n intramuscular en estas personas.\n- La eficacia de Nuvaxovid puede ser menor en individuos inmunodeprimidos.\n- La administraci\u00f3n de Nuvaxovid en el embarazo s\u00f3lo debe considerarse cuando los beneficios potenciales superen cualquier riesgo potencial para la madre y el feto.\n- Los efectos con Nuvaxovid pueden afectar temporalmente a la capacidad de conducir o utilizar m\u00e1quinas.\n- Las personas pueden no estar completamente protegidas hasta siete d\u00edas despu\u00e9s de su segunda dosis. Como ocurre con todas las vacunas, la vacunaci\u00f3n con Nuvaxovid puede no proteger a todos los receptores de la vacuna.\n- Las reacciones adversas m\u00e1s comunes observadas durante los estudios cl\u00ednicos fueron dolor de cabeza, n\u00e1useas o v\u00f3mitos, mialgia, artralgia, sensibilidad/dolor en el lugar de la inyecci\u00f3n, fatiga y malestar.\nPara m\u00e1s informaci\u00f3n sobre Nuvaxovid, visite los siguientes sitios web:\nAcerca de NVX-CoV2373\nNVX-CoV2373 es una vacuna basada en prote\u00ednas dise\u00f1ada a partir de la primera secuencia gen\u00e9tica del SARS-CoV-2, el virus que causa la enfermedad de la COVID-19. La vacuna fue creada utilizando la tecnolog\u00eda de nanopart\u00edculas recombinantes de Novavax para generar ant\u00edgenos derivados de la prote\u00edna espiga (S) del coronavirus y est\u00e1 formulada con Matrix-M\u2122, el adyuvante basado en saponinas patentado de Novavax, para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes. NVX-CoV2373 contiene ant\u00edgenos de prote\u00edna purificados y no puede replicarse ni causar la COVID-19.\nLa vacuna de la COVID-19 de Novavax est\u00e1 empaquetada como una formulaci\u00f3n l\u00edquida lista para usar en un vial que contiene diez dosis. El r\u00e9gimen de vacunaci\u00f3n requiere dos dosis de 0,5 ml (5 mcg de ant\u00edgeno y 50 mcg de adyuvante Matrix-M) administradas por v\u00eda intramuscular con 21 d\u00edas de diferencia. La vacuna se almacena entre 2\u00b0 y 8\u00b0 Celsius, lo que permite utilizar los canales de suministro de vacunas y de cadena de fr\u00edo existentes. El uso de la vacuna debe estar de acuerdo con las recomendaciones oficiales.\nNovavax ha establecido asociaciones para la fabricaci\u00f3n, comercializaci\u00f3n y distribuci\u00f3n de NVX-CoV2373 en todo el mundo. Las autorizaciones existentes aprovechan la asociaci\u00f3n de fabricaci\u00f3n de Novavax con Serum Institute of India, el fabricante de vacunas m\u00e1s grande del mundo por volumen. Posteriormente se complementar\u00e1n con datos de sitios de fabricaci\u00f3n adicionales a lo largo de la cadena de suministro global de Novavax.\nAcerca de los ensayos de fase 3 de NVX-CoV2373\nNVX-CoV2373 se est\u00e1 evaluando en dos ensayos fundamentales de fase 3.\nPREVENT-19 (PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) es un ensayo aleatorio 2:1, controlado con placebo, observador ciego para evaluar la eficacia, seguridad e inmunogenicidad de NVX-CoV2373 con el adyuvante Matrix-M en 29.960 participantes mayores de 18 a\u00f1os en m\u00e1s de 119 localizaciones de Estados Unidos y M\u00e9xico. El criterio principal de valoraci\u00f3n para PREVENT-19 fue la primera aparici\u00f3n de la COVID-19 sintom\u00e1tico (leve, moderado o grave) confirmado por PCR con inicio al menos 7 d\u00edas despu\u00e9s de la segunda dosis en participantes adultos serol\u00f3gicamente negativos (para SARS-CoV-2) en base. El criterio de \u00e9xito estad\u00edstico inclu\u00eda un l\u00edmite inferior de IC del 95% >30%. Un criterio de valoraci\u00f3n secundario fue la prevenci\u00f3n de la COVID-19 sintom\u00e1tica moderada o grave confirmada por PCR. Ambos criterios de valoraci\u00f3n se evaluaron al menos siete d\u00edas despu\u00e9s de la segunda vacunaci\u00f3n del estudio en voluntarios que no hab\u00edan sido infectados previamente con SARS-CoV-2. En el ensayo, NVX-CoV2373 alcanz\u00f3 una eficacia global del 90,4%. En general, fue bien tolerado y provoc\u00f3 una s\u00f3lida respuesta de anticuerpos tras la segunda dosis en ambos estudios. Los resultados completos del ensayo se publicaron en el\n[New EnglandJournalof Medicine](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2638908843&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3490095-1%26h%3D276014382%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D467849857%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+EnglandJournalof+Medicine) (NEJM).\nLa ampliaci\u00f3n pedi\u00e1trica de PREVENT-19 es un ensayo aleatorio 2:1, controlado con placebo y ciego por un observador para evaluar la seguridad, la efectividad y la eficacia de NVX-CoV2373 con el adyuvante Matrix-M en 2.247 participantes adolescentes de 12 a 17 a\u00f1os de edad en 73 lugares de los Estados Unidos, en comparaci\u00f3n con el placebo. En el ensayo pedi\u00e1trico, NVX-CoV2373 alcanz\u00f3 su criterio de valoraci\u00f3n de la eficacia primaria (no inferioridad de la respuesta de anticuerpos neutralizantes en comparaci\u00f3n con los participantes adultos j\u00f3venes de 18 a 25 a\u00f1os de edad de PREVENT-19) y demostr\u00f3 una eficacia global del 80% en un momento en que la variante Delta de inter\u00e9s era la cepa predominante que circulaba en Estados Unidos. Adem\u00e1s, la respuesta inmunitaria fue entre dos y tres veces mayor en los adolescentes que en los adultos contra todas las variantes estudiadas.\nPREVENT-19 se est\u00e1 llevando a cabo con el apoyo del gobierno de los Estados Unidos, incluyendo el Departamento de Defensa, la Autoridad de Investigaci\u00f3n y Desarrollo Biom\u00e9dico Avanzado (BARDA), parte de la Oficina del Subsecretario de Preparaci\u00f3n y Respuesta del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS), y el Instituto Nacional de Alergias y Enfermedades Infecciosas, parte de los Institutos Nacionales de Salud del HHS. BARDA proporciona hasta 1.750 millones de d\u00f3lares en virtud de un acuerdo del Departamento de Defensa (# MCDC2011-001).\nUn ensayo llevado a cabo en Reino Unido con 14.039 participantes de m\u00e1s de 18 a\u00f1os fue dise\u00f1ado como un estudio aleatorio, controlado con placebo y ciego para el observador, y alcanz\u00f3 una eficacia global del 89,7%. El criterio de valoraci\u00f3n primario se bas\u00f3 en la primera aparici\u00f3n de la COVID-19 sintom\u00e1tica (leve, moderada o grave) confirmada por PCR con inicio al menos 7 d\u00edas despu\u00e9s de la segunda vacunaci\u00f3n del estudio en participantes adultos serol\u00f3gicamente negativos (al SARS-CoV-2) al inicio. Los resultados completos del ensayo se publicaron en\n[NEJM](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4040707067&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2148733100%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D3617137863%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2107659%2526a%253DNEJM%26a%3DNEJM&a=NEJM).\nAcerca del adyuvante Matrix-M\u2122\nEl adyuvante Matrix-M\u2122 a base de saponina patentado de Novavax ha demostrado un efecto potente y bien tolerado al estimular la entrada de c\u00e9lulas presentadoras de ant\u00edgenos en el lugar de la inyecci\u00f3n y mejorar la presentaci\u00f3n de ant\u00edgenos en los ganglios linf\u00e1ticos locales, lo que aumenta la respuesta inmunitaria.\nAcerca de Novavax\nNovavax, Inc. (Nasdaq:\n[NVAX](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=918722110&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Des%26o%3D3394048-1%26h%3D3436167745%26u%3Dhttps%253A%252F%252Fwww.prnewswire.com%252Fnews-releases%252Fnovavax-y-serum-institute-of-india-reciben-la-autorizacion-de-uso-en-emergencia-de-la-vacuna-contra-la-covid-19-en-indonesia-823913107.html%2523financial-modal%26a%3DNVAX&a=NVAX)) es una empresa de biotecnolog\u00eda que promueve la mejora de la salud a nivel mundial mediante el descubrimiento, el desarrollo y la comercializaci\u00f3n de vacunas innovadoras para prevenir enfermedades infecciosas graves. La plataforma de tecnolog\u00eda recombinante patentada de la empresa combina el poder y la velocidad de la ingenier\u00eda gen\u00e9tica para producir de manera eficiente nanopart\u00edculas altamente inmunog\u00e9nicas dise\u00f1adas para atender las necesidades urgentes de salud en todo el mundo. NVX-CoV2373, la vacuna de la COVID-19 de la empresa, ha recibido la autorizaci\u00f3n condicional de m\u00faltiples autoridades reguladoras de todo el mundo, incluidas la Comisi\u00f3n Europea y la Organizaci\u00f3n Mundial de la Salud. La vacuna est\u00e1 siendo revisada por m\u00faltiples agencias reguladoras en todo el mundo y pronto lo ser\u00e1 en Estados Unidos para su uso en adultos, adolescentes y como refuerzo.Adem\u00e1s de su vacuna COVID-19, Novavax tambi\u00e9n est\u00e1 evaluando actualmente un candidato a vacuna combinada contra la gripe estacional COVID en un ensayo cl\u00ednico de fase 1/2, que combina NVX-CoV2373 y NanoFlu*, su candidato a vacuna tetravalente contra la gripe en investigaci\u00f3n, y tambi\u00e9n est\u00e1 evaluando una vacuna basada en la cepa Omicron (NVX-CoV2515), as\u00ed como una vacuna bivalente basada en la cepa Omicron / original. Estas vacunas candidatas incorporan el adyuvante Matrix-M\u2122, propiedad de Novavax, basado en saponinas, para mejorar la respuesta inmunitaria y estimular altos niveles de anticuerpos neutralizantes.\nPara m\u00e1s informaci\u00f3n, visite\n[www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3703664081&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3490095-1%26h%3D2841185550%26u%3Dhttp%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com) y conecte con nosotros en\n*NanoFlu identifica un candidato a vacuna antigripal de nanopart\u00edculas de prote\u00edna de hemaglutinina (HA) recombinante producido por Novavax. Este candidato en investigaci\u00f3n fue evaluado durante un ensayo controlado de fase 3 realizado durante la temporada de gripe 2019-2020.\nDeclaraciones prospectivas\nLas declaraciones en este documento relacionadas con el futuro de Novavax, sus planes operativos y perspectivas, sus asociaciones, el momento de los resultados de los ensayos cl\u00ednicos, el desarrollo continuo de NVX-CoV2373, un candidato a vacuna contra la gripe estacional COVID, el alcance, el calendario y el resultado de futuras presentaciones y acciones regulatorias, incluyendo los planes de Novavax de complementar las autorizaciones existentes con datos de los sitios de fabricaci\u00f3n adicionales en la cadena de suministro global de Novavax, las autorizaciones mundiales adicionales de NVX-CoV2373 para adolescentes, el impacto potencial y el alcance de Novavax y NVX-CoV2373 para abordar el acceso a la vacuna, controlar la pandemia y proteger a las poblaciones, y la eficacia, seguridad y utilizaci\u00f3n prevista de NVX-CoV2373 son declaraciones de futuro. Novavax advierte que estas declaraciones prospectivas est\u00e1n sujetas a numerosos riesgos e incertidumbres que podr\u00edan causar que los resultados reales difieran materialmente de los expresados o impl\u00edcitos en dichas declaraciones. Estos riesgos e incertidumbres incluyen, entre otros, desaf\u00edos para satisfacer, solo o junto con socios, varios requisitos de seguridad, eficacia y caracterizaci\u00f3n de productos, incluidos los relacionados con la calificaci\u00f3n del proceso y la validaci\u00f3n del ensayo, necesarios para satisfacer a las autoridades reguladoras aplicables; dificultad para obtener materias primas y suministros escasos; limitaciones de recursos, incluido el capital humano y la capacidad de fabricaci\u00f3n, sobre la capacidad de Novavax para seguir las v\u00edas normativas planificadas; desaf\u00edos para cumplir con los requisitos contractuales en virtud de acuerdos con m\u00faltiples entidades comerciales, gubernamentales y de otro tipo; y aquellos otros factores de riesgo identificados en las secciones \"Factores de riesgo\" y \"Debate y an\u00e1lisis de la administraci\u00f3n de la situaci\u00f3n financiera y los resultados de las operaciones\" del Informe anual de Novavax en el Formulario 10-K para el a\u00f1o finalizado el 31 de diciembre de 2021, y los posteriores informes trimestrales en el formulario 10-Q,tal como se present\u00f3 ante el Comisi\u00f3n de Bolsa y Valores (SEC). Advertimos a los inversores que no conf\u00eden demasiado en las declaraciones prospectivas contenidas en este comunicado de prensa. Le animamos a leer nuestras presentaciones ante la SEC, disponibles\n[www.sec.gov](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3230603101&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3560647-1%26h%3D633656546%26u%3Dhttps%253A%252F%252Foneomnicom.sharepoint.com%252Fsites%252FNovavax311%252FShared%252520Documents%252FGeneral%252FNewsflow%252F0422%252520EMA%252520Pediatric%252520Authorization%252Fwww.sec.gov%26a%3Dwww.sec.gov&a=www.sec.gov) y [www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3667471726&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3560647-1%26h%3D2408286918%26u%3Dhttps%253A%252F%252Foneomnicom.sharepoint.com%252Fsites%252FNovavax311%252FShared%252520Documents%252FGeneral%252FNewsflow%252F0422%252520EMA%252520Pediatric%252520Authorization%252Fwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com), para una discusi\u00f3n de estos y otros riesgos e incertidumbres. Las declaraciones de futuro en este comunicado de prensa se refieren solo a la fecha de este documento, y no asumimos ninguna obligaci\u00f3n de actualizar o revisar ninguna de las declaraciones. Nuestro negocio est\u00e1 sujeto a riesgos e incertidumbres sustanciales, incluidos los mencionados anteriormente. Los inversores, los inversores potenciales y otros deben considerar cuidadosamente estos riesgos e incertidumbres.\nContactos:\nInversores\nAlex Delacroix | 240-268-2022\n[[email protected]](/cdn-cgi/l/email-protection#6a03182a04051c0b1c0b1244090507)\nMedios\nAli Chartan | 240-720-7804\n[[email protected]](/cdn-cgi/l/email-protection#cea3abaaa7af8ea0a1b8afb8afb6e0ada1a3)\nLogo -\n[https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4098355291&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2132339007%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg)\nSOURCE Novavax, Inc.", "language": null, "image": "https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg?p=facebook", "pagetype": "articles", "links": ["/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "https://portal.prnewswire.com/Login.aspx", "https://www.prnewswire.com/account/online-membership-form/", "https://gdpr.cision.com/", "https://portal.prnewswire.com/Login.aspx", "/", "/news-releases/", "/products/overview/", "/contact-us/", "#", "/news-releases/", "/news-releases/news-releases-list/", "/news-releases/all-public-company-news/", "/news-releases/english-releases/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/multimedia/multimedia-list/", "/news-releases/photos/photos-list/", "/news-releases/videos/videos-list/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/latest-news-topics/", "#", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/automotive-transportation-latest-news/aerospace-defense-list/", "/news-releases/automotive-transportation-latest-news/air-freight-list/", "/news-releases/automotive-transportation-latest-news/airlines-aviation-list/", "/news-releases/automotive-transportation-latest-news/automotive-list/", "/news-releases/automotive-transportation-latest-news/maritime-shipbuilding-list/", "/news-releases/automotive-transportation-latest-news/railroads-and-intermodal-transportation-list/", "/news-releases/automotive-transportation-latest-news/supply-chain-logistics-list/", "/news-releases/automotive-transportation-latest-news/transportation-trucking-railroad-list/", "/news-releases/automotive-transportation-latest-news/travel-list/", "/news-releases/automotive-transportation-latest-news/trucking-and-road-transportation-list/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/business-technology-latest-news/blockchain-list/", "/news-releases/business-technology-latest-news/broadcast-tech-list/", "/news-releases/business-technology-latest-news/computer-electronics-list/", "/news-releases/business-technology-latest-news/computer-hardware-list/", "/news-releases/business-technology-latest-news/computer-software-list/", "/news-releases/business-technology-latest-news/data-analytics-list/", "/news-releases/business-technology-latest-news/electronic-commerce-list/", "/news-releases/business-technology-latest-news/electronic-components-list/", "/news-releases/business-technology-latest-news/electronic-design-automation-list/", "/news-releases/business-technology-latest-news/financial-technology-list/", "/news-releases/business-technology-latest-news/high-tech-security-list/", "/news-releases/business-technology-latest-news/internet-technology-list/", "/news-releases/business-technology-latest-news/nanotechnology-list/", "/news-releases/business-technology-latest-news/networks-list/", "/news-releases/business-technology-latest-news/peripherals-list/", "/news-releases/business-technology-latest-news/semiconductors-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/financial-services-latest-news/accounting-news-issues-list/", "/news-releases/financial-services-latest-news/acquisitions-mergers-and-takeovers-list/", "/news-releases/financial-services-latest-news/banking-financial-services-list/", "/news-releases/financial-services-latest-news/bankruptcy-list/", "/news-releases/financial-services-latest-news/bond-stock-ratings-list/", "/news-releases/financial-services-latest-news/conference-call-announcements-list/", "/news-releases/financial-services-latest-news/contracts-list/", "/news-releases/financial-services-latest-news/cryptocurrency-list/", "/news-releases/financial-services-latest-news/dividends-list/", "/news-releases/financial-services-latest-news/earnings-list/", "/news-releases/financial-services-latest-news/earnings-forecasts-projections-list/", "/news-releases/financial-services-latest-news/financing-agreements-list/", "/news-releases/financial-services-latest-news/insurance-list/", "/news-releases/financial-services-latest-news/investment-opinions-list/", "/news-releases/financial-services-latest-news/joint-ventures-list/", "/news-releases/financial-services-latest-news/mutual-funds-list/", "/news-releases/financial-services-latest-news/private-placement-list/", "/news-releases/financial-services-latest-news/real-estate-list/", "/news-releases/financial-services-latest-news/restructuring-recapitalization-list/", "/news-releases/financial-services-latest-news/sales-reports-list/", "/news-releases/financial-services-latest-news/shareholder-activism-list/", "/news-releases/financial-services-latest-news/shareholder-meetings-list/", "/news-releases/financial-services-latest-news/stock-offering-list/", "/news-releases/financial-services-latest-news/stock-split-list/", "/news-releases/financial-services-latest-news/venture-capital-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "/news-releases/general-business-latest-news/awards-list/", "/news-releases/general-business-latest-news/commercial-real-estate-list/", "/news-releases/general-business-latest-news/corporate-expansion-list/", "/news-releases/general-business-latest-news/earnings-list/", "/news-releases/general-business-latest-news/environmental-social-governance-list/", "/news-releases/general-business-latest-news/human-resource-workforce-management-list/", "/news-releases/general-business-latest-news/licensing-list/", "/news-releases/general-business-latest-news/new-products-services-list/", "/news-releases/general-business-latest-news/obituaries-list/", "/news-releases/general-business-latest-news/outsourcing-businesses-list/", "/news-releases/general-business-latest-news/overseas-real-estate-list/", "/news-releases/general-business-latest-news/personnel-announcements-list/", "/news-releases/general-business-latest-news/real-estate-transactions-list/", "/news-releases/general-business-latest-news/residential-real-estate-list/", "/news-releases/general-business-latest-news/small-business-services-list/", "/news-releases/general-business-latest-news/socially-responsible-investing-list/", "/news-releases/general-business-latest-news/surveys-polls-and-research-list/", "/news-releases/general-business-latest-news/trade-show-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "#", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/consumer-technology-latest-news/artificial-intelligence-list/", "/news-releases/consumer-technology-latest-news/blockchain-list/", "/news-releases/consumer-technology-latest-news/cloud-computing-internet-of-things-list/", "/news-releases/consumer-technology-latest-news/computer-electronics-list/", "/news-releases/consumer-technology-latest-news/computer-hardware-list/", "/news-releases/consumer-technology-latest-news/computer-software-list/", "/news-releases/consumer-technology-latest-news/consumer-electronics-list/", "/news-releases/consumer-technology-latest-news/cryptocurrency-list/", "/news-releases/consumer-technology-latest-news/data-analytics-list/", "/news-releases/consumer-technology-latest-news/electronic-commerce-list/", "/news-releases/consumer-technology-latest-news/electronic-gaming-list/", "/news-releases/consumer-technology-latest-news/financial-technology-list/", "/news-releases/consumer-technology-latest-news/mobile-entertainment-list/", "/news-releases/consumer-technology-latest-news/multimedia-internet-list/", "/news-releases/consumer-technology-latest-news/peripherals-list/", "/news-releases/consumer-technology-latest-news/social-media-list/", "/news-releases/consumer-technology-latest-news/science-tech-engineering-math-list/", "/news-releases/consumer-technology-latest-news/supply-chain-logistics-list/", "/news-releases/consumer-technology-latest-news/wireless-communications-list/", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/energy-latest-news/alternative-energies-list/", "/news-releases/energy-latest-news/chemical-list/", "/news-releases/energy-latest-news/electrical-utilities-list/", "/news-releases/energy-latest-news/gas-list/", "/news-releases/energy-latest-news/general-manufacturing-list/", "/news-releases/energy-latest-news/mining-list/", "/news-releases/energy-latest-news/mining-metals-list/", "/news-releases/energy-latest-news/oil-energy-list/", "/news-releases/energy-latest-news/oil-and-gas-discoveries-list/", "/news-releases/energy-latest-news/utilities-list/", "/news-releases/energy-latest-news/water-utilities-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/environment-latest-news/conservation-recycling-list/", "/news-releases/environment-latest-news/environmental-issues-list/", "/news-releases/environment-latest-news/environmental-policy-list/", "/news-releases/environment-latest-news/environmental-products-services-list/", "/news-releases/environment-latest-news/green-technology-list/", "/news-releases/environment-latest-news/natural-disasters/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/aerospace-defense-list/", "/news-releases/heavy-industry-manufacturing-latest-news/agriculture-list/", "/news-releases/heavy-industry-manufacturing-latest-news/chemical-list/", "/news-releases/heavy-industry-manufacturing-latest-news/construction-building-list/", "/news-releases/heavy-industry-manufacturing-latest-news/general-manufacturing-list/", "/news-releases/heavy-industry-manufacturing-latest-news/hvac-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machinery-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machine-tools-metalworking-and-metallury-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/paper-forest-products-containers-list/", "/news-releases/heavy-industry-manufacturing-latest-news/precious-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/textiles-list/", "/news-releases/heavy-industry-manufacturing-latest-news/tobacco-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "/news-releases/telecommunications-latest-news/carriers-and-services-list/", "/news-releases/telecommunications-latest-news/mobile-entertainment-list/", "/news-releases/telecommunications-latest-news/networks-list/", "/news-releases/telecommunications-latest-news/peripherals-list/", "/news-releases/telecommunications-latest-news/telecommunications-equipment-list/", "/news-releases/telecommunications-latest-news/telecommunications-industry-list/", "/news-releases/telecommunications-latest-news/voip-list/", "/news-releases/telecommunications-latest-news/wireless-communications-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "#", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/consumer-products-retail-latest-news/animals-pets-list/", "/news-releases/consumer-products-retail-latest-news/beers-wines-and-spirits-list/", "/news-releases/consumer-products-retail-latest-news/beverages-list/", "/news-releases/consumer-products-retail-latest-news/bridal-services-list/", "/news-releases/consumer-products-retail-latest-news/cannabis-list/", "/news-releases/consumer-products-retail-latest-news/cosmetics-and-personal-care-list/", "/news-releases/consumer-products-retail-latest-news/fashion-list/", "/news-releases/consumer-products-retail-latest-news/food-beverages-list/", "/news-releases/consumer-products-retail-latest-news/furniture-and-furnishings-list/", "/news-releases/consumer-products-retail-latest-news/home-improvements-list/", "/news-releases/consumer-products-retail-latest-news/household-consumer-cosmetics-list/", "/news-releases/consumer-products-retail-latest-news/household-products-list/", "/news-releases/consumer-products-retail-latest-news/jewelry-list/", "/news-releases/consumer-products-retail-latest-news/non-alcoholic-beverages-list/", "/news-releases/consumer-products-retail-latest-news/office-products-list/", "/news-releases/consumer-products-retail-latest-news/organic-food-list/", "/news-releases/consumer-products-retail-latest-news/product-recalls-list/", "/news-releases/consumer-products-retail-latest-news/restaurants-list/", "/news-releases/consumer-products-retail-latest-news/retail-list/", "/news-releases/consumer-products-retail-latest-news/supermarkets-list/", "/news-releases/consumer-products-retail-latest-news/toys-list/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/health-latest-news/biometrics-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/clinical-trials-medical-discoveries-list/", "/news-releases/health-latest-news/dentistry-list/", "/news-releases/health-latest-news/fda-approval-list/", "/news-releases/health-latest-news/fitness-wellness-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/health-insurance-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/international-medical-approval-list/", "/news-releases/health-latest-news/medical-equipment-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/mental-health-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/supplementary-medicine-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/sports-latest-news/general-sports-list/", "/news-releases/sports-latest-news/outdoors-camping-hiking-list/", "/news-releases/sports-latest-news/sporting-events-list/", "/news-releases/sports-latest-news/sports-equipment-accessories-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "/news-releases/travel-latest-news/amusement-parks-and-tourist-attractions-list/", "/news-releases/travel-latest-news/gambling-casinos-list/", "/news-releases/travel-latest-news/hotels-and-resorts-list/", "/news-releases/travel-latest-news/leisure-tourism-list/", "/news-releases/travel-latest-news/outdoors-camping-hiking-list/", "/news-releases/travel-latest-news/passenger-aviation-list/", "/news-releases/travel-latest-news/travel-industry-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "#", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "/news-releases/policy-public-interest-latest-news/advocacy-group-opinion-list/", "/news-releases/policy-public-interest-latest-news/animal-welfare-list/", "/news-releases/policy-public-interest-latest-news/congressional-presidential-campaigns-list/", "/news-releases/policy-public-interest-latest-news/corporate-social-responsibility-list/", "/news-releases/policy-public-interest-latest-news/domestic-policy-list/", "/news-releases/policy-public-interest-latest-news/economic-news-trends-analysis-list/", "/news-releases/policy-public-interest-latest-news/education-list/", "/news-releases/policy-public-interest-latest-news/environmental-list/", "/news-releases/policy-public-interest-latest-news/european-government-list/", "/news-releases/policy-public-interest-latest-news/fda-approval-list/", "/news-releases/policy-public-interest-latest-news/federal-and-state-legislation-list/", "/news-releases/policy-public-interest-latest-news/federal-executive-branch-agency-news-list/", "/news-releases/policy-public-interest-latest-news/foreign-policy-international-affairs-list/", "/news-releases/policy-public-interest-latest-news/homeland-security-list/", "/news-releases/policy-public-interest-latest-news/labor-union-news-list/", "/news-releases/policy-public-interest-latest-news/legal-issues-list/", "/news-releases/policy-public-interest-latest-news/natural-disasters-list/", "/news-releases/policy-public-interest-latest-news/not-for-profit-list/", "/news-releases/policy-public-interest-latest-news/patent-law-list/", "/news-releases/policy-public-interest-latest-news/public-safety-list/", "/news-releases/policy-public-interest-latest-news/trade-policy-list/", "/news-releases/policy-public-interest-latest-news/us-state-policy-news-list/", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "#", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/news-releases/multicultural-latest-news/native-american-list/", "/news-releases/multicultural-latest-news/african-american-related-news-list/", "/news-releases/multicultural-latest-news/asian-related-news-list/", "/news-releases/multicultural-latest-news/children-related-news-list/", "/news-releases/multicultural-latest-news/diversity-equity-inclusion/", "/news-releases/multicultural-latest-news/hispanic-oriented-news-list/", "/news-releases/multicultural-latest-news/lesbian-gay-bisexual-list/", "/news-releases/multicultural-latest-news/mens-interest-list/", "/news-releases/multicultural-latest-news/people-with-disabilities-list/", "/news-releases/multicultural-latest-news/religion-list/", "/news-releases/multicultural-latest-news/senior-citizens-list/", "/news-releases/multicultural-latest-news/veterans-list/", "/news-releases/multicultural-latest-news/women-related-news-list/", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/ae/ar/news-releases/", "/comunicados-de-prensa/", "/comunicados-para-a-imprensa/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/de/pressemitteilungen/", "/es/comunicados-de-prensa/", "/fr/communiques-de-presse/", "/it/comunicati-stampa/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/fi/lehdistotiedotteet/", "/sv/pressmeddelanden/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/guaranteed-paid-placement/", "/products/all-products/", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "#nav-mobile", "/", "https://portal.prnewswire.com", "/contact-us/", "javascript:void(0)", "/contact-us/", "/contact-us/", "tel:+1-888-776-0942", "javascript:void(0)", "#", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/business-technology-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/financial-services-latest-news/", "/news-releases/general-business-latest-news/", "/news-releases/consumer-technology-latest-news/", "/news-releases/energy-latest-news/", "/news-releases/environment-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/telecommunications-latest-news/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/health-latest-news/", "/news-releases/sports-latest-news/", "/news-releases/travel-latest-news/", "/news-releases/multicultural-latest-news/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/products/all-products/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/contact-us/#general", "/request-a-demo/", "/contact-us/#editorial", "/contact-us/#partnerships", "/contact-us/#media", "/contact-us/#worldwide", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/in/news-releases/novavax-nuvaxovid-tm-covid-19-vaccine-conditionally-authorized-in-the-european-union-for-adolescents-aged-12-through-17-810530420.html", "/news-releases/novavax-nuvaxovid-covid-19-vaccine-conditionally-authorized-in-the-european-union-for-adolescents-aged-12-through-17-301580570.html", "/news-releases/la-vacuna-nuvaxovid-tm-de-novavax-contra-la-covid-19-se-autoriza-de-forma-condicional-en-la-union-europea-para-adolescentes-de-12-a-17-anos-862528667.html", "/news-releases/l-utilisation-du-vaccin-contre-la-covid-19-nuvaxovid-tm-de-novavax-est-autorisee-sous-condition-au-sein-de-l-union-europeenne-pour-les-adolescents-ages-de-12-a-17-ans-887218858.html", "/news-releases/novavax-nuvaxovid-tm-covid-19-impfstoff-in-der-europaischen-union-fur-jugendliche-im-alter-von-12-bis-17-jahren-unter-vorbehalt-zugelassen-825562694.html", "#", "/news/novavax%2C-inc./", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", null, "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2297960184&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D4051581382%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-06-23-Novavax-COVID-19-Vaccine-Nuvaxovid-TM-Recommended-for-Expanded-Conditional-Marketing-Authorization-in-the-European-Union-by-CHMP-for-Adolescents-Aged-12-Through-17%26a%3DJune%2B23%252C%2B2022&a=23+de+junio+de+2022", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2892827951&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3028641640%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial%26a%3Dpediatric%2Bexpansion&a=ampliaci%C3%B3n+pedi%C3%A1trica", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2632041598&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D697197056%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D3782079808%2526u%253Dhttps%25253A%25252F%25252Fir.novavax.com%25252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%2526a%253DDecember%26a%3DDecember%2B2021&a=diciembre+de+2021", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=574237381&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3307428078%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-03-22-Novavax-and-Serum-Institute-of-India-Announce-First-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-in-Adolescents-12-to-18-in-India%26a%3DIndia&a=India", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4260100111&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1662690841%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D1545350530%2526u%253Dhttps%25253A%25252F%25252Fwww.ema.europa.eu%25252Fen%25252Fmedicines%25252Fhuman%25252FEPAR%25252Fnuvaxovid%2526a%253DEuropean%252BMedicines%252BAgency%26a%3DEuropean%2BMedicines%2BAgency&a=Agencia+Europea+del+Medicamento", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=1578647828&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D4294773337%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D2784477625%2526u%253Dhttps%25253A%25252F%25252Fec.europa.eu%25252Fcommission%25252Fpresscorner%25252Fdetail%25252Fen%25252Fip_21_6966%2526a%253DEuropean%252BCommission%26a%3DEuropean%2BCommission&a=Comisi%C3%B3n+Europea", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=1911842220&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1723901377%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3432645-1%2526h%253D3408202368%2526u%253Dhttps%25253A%25252F%25252Fwww.novavaxcovidvaccine.com%25252F%2526a%253Dglobal%252Bauthorization%252Bwebsite%26a%3DNovavax%2Bglobal%2Bauthorization%2Bwebsite&a=Sitio+web+de+la+autorizaci%C3%B3n+global+de+Novavax", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2638908843&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3490095-1%26h%3D276014382%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D467849857%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+EnglandJournalof+Medicine", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4040707067&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2148733100%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D3617137863%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2107659%2526a%253DNEJM%26a%3DNEJM&a=NEJM", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=918722110&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Des%26o%3D3394048-1%26h%3D3436167745%26u%3Dhttps%253A%252F%252Fwww.prnewswire.com%252Fnews-releases%252Fnovavax-y-serum-institute-of-india-reciben-la-autorizacion-de-uso-en-emergencia-de-la-vacuna-contra-la-covid-19-en-indonesia-823913107.html%2523financial-modal%26a%3DNVAX&a=NVAX", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3703664081&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3490095-1%26h%3D2841185550%26u%3Dhttp%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=734026&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2136702606%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D91088807%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D1725473980%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D2733326919%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D853375093%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D1325598136%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D2935962557%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D1508558197%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fc212.net%25252525252525252Fc%25252525252525252Flink%25252525252525252F%25252525252525253Ft%25252525252525253D0%252525252525252526l%25252525252525253Den%252525252525252526o%25252525252525253D3158017-1%252525252525252526h%25252525252525253D3702938248%252525252525252526u%25252525252525253Dhttps%2525252525252525253A%2525252525252525252F%2525252525252525252Fwww.linkedin.com%2525252525252525252Fcompany%2525252525252525252Fnovavax%2525252525252525252F%252525252525252526a%25252525252525253DLinkedIn%2525252525252526a%252525252525253DLinkedIn%25252525252526a%2525252525253DLinkedIn%252525252526a%25252525253DLinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%2525&a=LinkedIn", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3230603101&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3560647-1%26h%3D633656546%26u%3Dhttps%253A%252F%252Foneomnicom.sharepoint.com%252Fsites%252FNovavax311%252FShared%252520Documents%252FGeneral%252FNewsflow%252F0422%252520EMA%252520Pediatric%252520Authorization%252Fwww.sec.gov%26a%3Dwww.sec.gov&a=www.sec.gov", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3667471726&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3560647-1%26h%3D2408286918%26u%3Dhttps%253A%252F%252Foneomnicom.sharepoint.com%252Fsites%252FNovavax311%252FShared%252520Documents%252FGeneral%252FNewsflow%252F0422%252520EMA%252520Pediatric%252520Authorization%252Fwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com", "/cdn-cgi/l/email-protection#6a03182a04051c0b1c0b1244090507", "/cdn-cgi/l/email-protection#cea3abaaa7af8ea0a1b8afb8afb6e0ada1a3", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4098355291&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2132339007%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/energy-latest-news/mining-metals-list/", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "tel:Cision%20Distribution%20888-776-0942", "javascript://Chat", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "https://twitter.com/PRNewswire", "https://www.facebook.com/PR-Newswire-26247320522/", "https://www.linkedin.com/company/pr-newswire/", "/products/communications-cloud/", "/products/marketing/", "/products/public-relations/", "/products/ir-compliance/", "/products/agency/", "https://www.smallbusinesspr.com/request_information", "/products/all-products/", "https://prnewswire.mediaroom.com/index.php", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "/contact-us/prnewswire-partners/", "/contact-us/become-a-partner/", "https://www.cision.com/careers/", "https://www.cision.com/about/accessibility/", "https://www.prnasia.com/", "https://prnewswire.com.br/", "https://www.newswire.ca/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/fi/lehdistotiedotteet/", "/fr/communiques-de-presse/", "/de/pressemitteilungen/", "/in/news-releases/", "/il/news-releases/", "/it/comunicati-stampa/", "https://prnewswire.com.mx/", "/ae/news-releases/", "https://www.prnewswire.com/ae/ar/news-releases/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/es/comunicados-de-prensa/", "/sv/pressmeddelanden/", "https://www.prnewswire.co.uk/", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "/contact-us", "/products/overview", "https://prnewswire.mediaroom.com/index.php", "", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "tel:Cision%20Distribution%20Helpline", "/terms-of-use/", "/privacy-policy/", "/prn-information-security-policy/", "/sitemap/", "/rss/", "/cookie-settings/", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "javascript://Chat"]}